Activity of the alternative pathway of complement in the newborn infant.
Levels of C3, properdin, factor B, and C3 to C9 activity were markedly reduced in cord sera taken from 94 normal newborn infants. Nevertheless, cord serum supported complete activation of its own alternative pathway by zymosan or CoF. Lysis of a target cell, however, was defective; nearly 75% of cord sera had reduced rabbit erythrocyte CH50 titers. These were partially increased by the addition of factor B and properdin, and totally restored by adding factor B, properdin, and C3 to C9. Therefore, although the alternative pathway of the neonate is intact, it appears to be limited in its ability to generate an adequate number of stable and active enzymatic sites on a target cell membrane.
D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism; D011415:Complement Factor B / Q000378:metabolism; D011416:Complement Factor D / Q000097:blood; D003170:Complement Pathway, Alternative; D003165:Complement System Proteins / Q000378:metabolism; D005312:Fetal Blood; D006801:Humans; D007231:Infant, Newborn; D011414:Properdin / Q000378:metabolism
D003176:Complement C3; D011414:Properdin; D003165:Complement System Proteins; C493488:CFD protein, human; D011416:Complement Factor D; D011415:Complement Factor B